Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. (LIPO) Revenue
Annual & quarterly revenue history · segment & region breakdown
LIPO · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsLipella Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 19.29% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | +$0.00B | +19.29% |
| 2023-12-31 | $0.00B | +$0.00B | +144.15% |
| 2022-12-31 | $0.00B | -$0.00B | -28.99% |
| 2021-12-31 | $0.00B | -$0.00B | -73.03% |
| 2020-12-31 | $0.00B | +$0.00B | +38.42% |
| 2019-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Lipella Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Lipella Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Lipella Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
LIPO revenue · 4 questionsLIPO's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 19.29% year-over-year from $0.00B in FY2024.
▸ Source: FMP · Lipella Pharmaceuticals Inc. SEC filings · GAAP · Lipella Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026